Sector News

As Merck boosts R&D pact, NGM Bio gains Genentech, Lilly veteran as new R&D chief

March 20, 2019
Life sciences

It’s a pretty good news day for NGM Bio: Merck doubled down on its R&D pact, and it’s nabbed a Genentech executive to help run its trials.

The biotech sees Hsiao D. Lieu, M.D., become its new senior vice president and CMO, poaching him from Genentech, where he was VP of early clinical development at the Roche subsidiary for its noncancer work, including ophthalmology, metabolic, neurology and inflammation. Before Genentech, he was at Eli Lilly, working across several therapy areas.

Now, he’s taking the plunge into biotech waters, overseeing the clinical development of NGM’s pipeline, which includes its midstage NASH hopeful NGM282.

He takes over from Alex DePaoli, M.D., who had been NGM’s founding CMO and moves into a new role of SVP, chief translational officer.

CEO David Woodhouse said, “We are thrilled to welcome Hsiao to the NGM team. As we progress NGM282 into phase 2b studies in NASH in addition to several additional clinical programs, we look forward to leveraging Hsiao’s extensive experience leading early and late-stage clinical development across multiple therapeutic areas relevant to NGM.”

“I am excited to join NGM at this important time, given the company’s impressive scientific foundation and significant potential to help tackle some of today’s most critical unmet medical needs,” added Lieu.

“NGM has unlocked novel insights about powerful human biology and, in a relatively short amount of time, has transformed these findings into a deep pipeline of novel, first-in-class medicines for multiple therapeutic areas and diseases. I look forward to working closely with Alex and the rest of the team as we continue to translate NGM’s ongoing scientific accomplishments into potential breakthrough therapies for patients.”

Lieu joins Dave Goeddel, the first scientist hired at Genentech, who runs the biotech’s board of directors, with former Genentech CEO Art Levinson also on the biotech’s scientific advisory board.

This also comes on the same day NGM announced partner Merck will add two more years to its research pact with the biotech, although the shine was slightly less buffed after the Big Pharma also announced it was culling work on an NGM obesity drug, coming after it failed to make the grade in an early test last year.

The biotech filed for a $75 million IPO last year.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).